Objective To compare the effects of rosuvastatin and atorvastatin on serum myocardial injury markers levels in earlyonset acute myocardial infarction (AMI). Methods A total of 104 patients with early-onset AMI in our hospital were selected for the study and were divided into rosuvastatin group (observation group, n=52) and atorvastatin group (control group, n=52) according to the random number table method. The blood lipids levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)], inflammatory response [hypersensitive C-reactive protein (hs-CRP), milk fat globule epidermal growth factor 8 (MFG-E8)] and myocardial injury markers levels [creatine kinase isoenzyme (CK-MB), hypersensitive troponin T (hs-TnT)] were compared between the two groups before treatment and after 6 months of treatment. Results After 6 months of treatment, levels of serum LDL-C, hs-CRP, and plasma CK-MB and hs-TnT in the two groups were decreased compared with those before treatment (P<0.05) while levels of serum HDL-C and MFG-E8 were increased compared with those before treatment (P<0.05), and the changes in observation group were greater than those in control group (P<0.05). Conclusion Rosuvastatin and atorvastatin both have good effects in the treatment of early-onset AMI, but rosuvastatin is superior to atorvastatin in improving blood lipids regulation, inflammation inhibition and myocardial injury, and it is more favorable for disease outcomes.